Lipid-lowering therapy can be considered with a 10-year PREVENT-ASCVD risk estimate of 3% to <5% (borderline) and should be considered for those at 5% to <10% (intermediate) 10-year risk. For ...
Background Although the increased risk of cardiovascular disease in patients with SLE is well-documented, effective tools for risk stratification remain elusive. This study sought to explore the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results